• Keith Kerr, Christopher Wilkerson, Scott Shepard, HuiMahn Choi, and Ryan Kitagawa.
• Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center at Houston, TX, USA.
• Clin Neurol Neurosurg. 2016 Jan 1; 140: 85-90.

ObjectiveTo evaluate the risk of hemorrhagic complications associated with starting anti-platelet therapy (APT) after acute traumatic intracranial hemorrhage (tICH) and to examine the frequency of thrombotic complications.Patients And MethodsWe retrospectively identified all patients admitted to our institution with tICH that received APT during their initial hospitalization over a three-year period. We reviewed their demographics, hospital course, clinical indication and timing for initiation of APT, and complications.ResultsA total of 222 patients were identified. The median age and Injury Severity Score (ISS) was 61 and 21, respectively. Fifty (23%) patients required neurosurgical procedures. APTs were initiated due to a history of APT use in 91 patients (41%) and blunt cerebrovascular injury in 86 patients (38.6%). The median time from injury to starting APT was 4 days. Immediate complications including new or worsening hemorrhage occurred in 1 (<1%) patient. Delayed hemorrhagic complications occurred in 6 (4.7%) patients. Thrombotic events occurred in 21 (9.4%) patients prior to starting APT. Thirteen (5.8%) of these were potentially preventable.ConclusionThe risk of immediate and delayed intracranial hemorrhages from initiating APT after tICH must be weighed against the morbidity of delaying indicated thrombotic prophylaxis. Our initial data indicates that hemorrhagic complications are infrequent, and thrombotic complications can have significant clinical consequences. Our retrospective review provides the first rates of complications for this patient population.Copyright © 2015 Elsevier B.V. All rights reserved.

28 keywords...

hide…